This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
by Zacks Equity Research
BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.
Sanofi to Buy Vaccine Biotech Protein Sciences for $650M
by Zacks Equity Research
Sanofi (SNY), on Monday, announced plans to buy a Meriden, CT-based private vaccine biotech, Protein Sciences for an upfront payment of $650 million.
Prima Biomed's Intra-Tumor Study on Lead Candidate Approved
by Zacks Equity Research
Prima Biomed Ltd. (PBMD) announced that a new clinical study, INSIGHT, on its lead candidate IMP321 has received regulatory approval for initiation
Endo (ENDP) to Remove Opioid Pain Drug Opana ER from Market
by Zacks Equity Research
Endo International plc (ENDP) recently announced that it will withdraw opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA's request in June.
Bristol-Myers Gets FDA Nod for Orencia's Label Expansion
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).
Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that a phase III study, CheckMate-238, evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg met its primary endpoint at a planned interim analysis.
ProQR's Usher Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
ProQR Therapeutics N.V. (PRQR) announced that its key pipeline candidate, QRX-411, has been granted orphan drug designation by the FDA and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa.
Merck Falls as FDA Puts Hold on 3 Keytruda Myeloma Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) shares were down more than 1% in after-hours trading on Wednesday after the company announced that the FDA has placed a clinical hold on three combination studies of Keytruda in multiple myeloma, a form of blood cancer.
Incyte & Lilly's Olumiant Gets Marketing Approval in Japan
by Zacks Equity Research
Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva
Aduro Starts Phase II Combo Study with CRS-207 & Keytruda
by Zacks Equity Research
Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).
M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks
by Arpita Dutt
The biotech sector's fundamentals remain strong.
Esperion's Combo Cholesterol Candidate Enters Phase III
by Zacks Equity Research
Esperion Therapeutics, Inc. (ESPR) received positive feedback from the FDA for initiation of a phase III bridging study, evaluating the combination of bempedoic acid (180 mg) and Zetia (10 mg) for an LDL-C lowering indication.
Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.
AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger
by Eric Dutram
This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!
Merck's Keytruda on a Roll: Can it Retain the Momentum?
by Zacks Equity Research
As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma giant.
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
Ligand Gets Milestone Payment on Partner Drug FDA Approval
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics' pipeline candidate Baxdela (delafloxacin) was approved by the FDA.
Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More
by Zacks Equity Research
The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.
Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.
Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.
Merck Stalls Enrolment in Two Myeloma Studies of Keytruda
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that it is pausing two late-stage studies evaluating its anti-PD-1 therapy, Keytruda, as a combination therapy for the treatment of multiple melanoma, a form of blood cancer.
The Zacks Analyst Blog Highlights: Facebook, Wal-Mart, Merck, Kellogg and PACCAR
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Wal-Mart, Merck, Kellogg and PACCAR
Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises
by Zacks Equity Research
Inovio Pharmaceuticals, Inc (INO) initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human papillomavirus.